CHMP supports label extension of Leo Pharma's atopic eczema treatment
Adtralza, which is already on the eczema treatment market for adults, has now been recommended for treating patients with the skin disease who are as young as 12.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Danish drugmaker Leo Pharma’s atopic eczema treatment Adtralza (tralokinumab) should not be exclusive to adults, said the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) during its September meeting.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma leaves the door open for acquisitions
For subscribers
CHMP recommends approval of 12 drugs at September meeting
For subscribers
